In summary, we provide initial real-world evidence of reduced alcohol consumption in people with obesity taking Semaglutide or Tirzepatide medications, suggesting potential efficacy for treatment in AUD comorbid with obesity. Note: Beyond what is publicly available today, several studies from established research groups showing substantial anti-addictive effects have been submitted to journals and will be published in mid-2024
Research published in PubMed demonstrates that DSIPs influence on the GABAergic system contributes significantly to its sleep-promoting properties
Notably, the inclusion of tirzepatide and retatrutide, which are dual GLP1/glucosedependent insulinotropic polypeptide (GIP) and triple GLP1/GIP/glucagon agonists, respectively, may influence the safety profile due to the additional receptor activation
Association between tumor necrosis factor-alpha and diabetic peripheral neuropathy in patients with type 2 diabetes: a meta-analysis
According to NICE guideline NG28, GLP-1 receptor agonists should be considered when: Triple therapy (metformin and two other oral drugs) is not effective, not tolerated, or contraindicated The patient has a BMI 35 kg/m (or lower in people of Black, Asian and other minority ethnic groups) and specific obesity-related comorbidities The patient has a BMI 40% reduction in non-HDL cholesterol GLP-1 receptor agonist for glycaemic control and weight management (with secondary lipid benefits) Ezetimibe if non-HDL cholesterol reduction is insufficient Lifestyle interventions addressing diet, exercise, and weight Monitoring and follow-up are essential components of cholesterol management
E.EdebaliE.Bakirci
